Frontlight ResearchEarly access
Taking people in NetherlandsPhase 4
Methotrexate compared with prednisone as first treatment for sarcoidosis in the lungs
Compares methotrexate with prednisone as first treatment in adults with pulmonary sarcoidosis.
Key facts
- Who runs it
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
- Where
- 'S-Gravenhage, 's-Hertogenbosch, Amsterdam, Arnhem, Breda, Eindhoven, Enschede, Groningen, Heerlen, Leeuwarden, Leiden, Nieuwegein, Nijmegen, Rotterdam, Venlo, and Zwolle, NetherlandsSee the 18 sites
- Registry title
- The PREDMETH trial: Effectiveness of methotrexate versus prednisone as first-line therapy for pulmonary sarcoidosis – A randomized controlled trial
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 132 people, planned
- Started
- 19 Nov 2024
- Planned end
- 1 Mar 2025
- Type of study
- Interventional
- Record updated
- 19 November 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with sarcoidosis in the lungs who need treatment for the first time. It compares methotrexate with prednisone.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Sarcoidosis affecting the lung tissue, seen on X-ray or CT scan in the last three months. The lungs must need treatment.
- Earlier treatment
- No earlier treatment that weakens the immune system for sarcoidosis. No such treatment for another disease in the past three months.
- Biomarker or test result
- Lung tests must show FVC ≤90% of predicted, or DLCO ≤70% of predicted, or a drop of ≥5% FVC or ≥10% DLCO in the past year.
Main reasons for not taking part
- Pregnant, breastfeeding, or planning pregnancy, breastfeeding or fathering a child during the study or within 90 days after the last dose
- Severe kidney problems (creatinine clearance <30 ml/min) or liver problems (bilirubin >5 mg/dl or 85,5 micromole/l)
- Bone marrow problems with very low white cells, platelets or red cells
- Severe infections such as tuberculosis, HIV, parasites or other immune weakness
- Ulcers in the mouth, stomach or duodenum
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Diagnosis of sarcoidosis according to the ATS/ERS/WASOG criteria (7), in case of absent histology a diagnosis of sarcoidosis can also be established in a multidisciplinary team meeting in a sarcoidosis expert center based on a highly suggestive clinical and radiological picture (18, 19)
- Age ≥18 years
- A pulmonary indication for treatment and parenchymal involvement on X-ray or CT-scan conducted within three months before inclusion (determined by the treating physician and conform current guidelines)
- A forced vital capacity (FVC) of ≤90% of predicted, or a diffusion capacity of the lung for carbon monoxide (DLCO) ≤70% of predicted, or ≥5% FVC decline/≥10% DLCO decline in the past year. For pulmonary functions tests GLI reference values are used
Who cannot take part
- Previous immunosuppressive treatment for sarcoidosis
- Any condition or circumstance that, in the opinion of the investigator, may make a subject unlikely or unable to complete the study or comply with study procedures
- Use of systemic immunosuppressive therapy within the preceding three months for another disease than sarcoidosis
- Contra-indication for methotrexate or corticosteroids: • severely impaired renal function (creatinine clearance <30 ml/min) • impaired hepatic function (serum bilirubin-value >5 mg/dl or 85,5 micromole/l) • bone marrow insufficiency with severe leukopenia, thrombocytopenia, or anaemia • severe acute or chronic infections, such as tuberculosis, HIV, parasitic infections or other immunodeficiency syndromes • mouth, stomach or duodenal ulcers
- Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study treatment or within 90 days after the last dose in the randomized study phase. For males; planning to pro-create during the study or within 90 days after the last dose of the randomized study phase
Where in Netherlands
- Haaglanden Medisch Centrum Stichting'S-Gravenhage, NetherlandsTaking people
- Jeroen Bosch Hospital's-Hertogenbosch, NetherlandsTaking people
- Academisch Medisch CentrumAmsterdam, NetherlandsTaking people
- OLVGAmsterdam, NetherlandsTaking people
- Vrije UniversiteitAmsterdam, NetherlandsTaking people
- Rijnstate Ziekenhuis StichtingArnhem, NetherlandsTaking people
- Amphia HospitalBreda, NetherlandsTaking people
- Catharina Ziekenhuis StichtingEindhoven, NetherlandsTaking people
- Medisch Spectrum TwenteEnschede, NetherlandsTaking people
- Stichting Martini ZiekenhuisGroningen, NetherlandsTaking people
- Zuyderland Medisch Centrum StichtingHeerlen, NetherlandsTaking people
- Medisch Centrum Leeuwarden B.V.Leeuwarden, NetherlandsTaking people
- LUMCLeiden, NetherlandsTaking people
- Sint Antonius Ziekenhuis StichtingNieuwegein, NetherlandsTaking people
- Canisius Wilhelmina ZiekenhuisNijmegen, NetherlandsTaking people
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, NetherlandsTaking people
- Stichting Viecuri Medisch Centrum voor Noord-LimburgVenlo, NetherlandsTaking people
- Isala Klinieken StichtingZwolle, NetherlandsTaking people
About the trial
What the trial wants to find out
Investigate the effectiveness and tolerability of methotrexate as firstline therapy in patients with pulmonary sarcoidosis compared with prednisone.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- The PREDMETH trial: Effectiveness of methotrexate versus prednisone as first-line therapy for pulmonary sarcoidosis - A randomized controlled trial
- Plain-language title
- Methotrexate compared with prednisone as first treatment for sarcoidosis in the lungsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 19 November 2024